SCHEMBL29429240

SCHEMBL29429240

O=C(O)[C@H](Cc1c[nH]c2ccccc12)NI

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.67
ACE P12821 3/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
KDM4E B2RXH2 2/20 0.63
MAPT P10636 2/20 0.63
APAF1 O14727 1/20 0.63
POLB P06746 1/20 0.63
RECQL P46063 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
MEN1 O00255 1/20 0.63
LMNA P02545 1/20 0.63
MPO P05164 1/20 0.63
TSHR P16473 1/20 0.63
BLM P54132 1/20 0.63
PMP22 Q01453 1/20 0.63
KMT2A Q03164 1/20 0.63
HIF1A Q16665 1/20 0.63
ITGB2 P05107 3/20 0.62
ICAM1 P05362 3/20 0.62
ITGAL P20701 3/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20816097 1.00 ALOX15 (0.67) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL18830959 1.00 ALOX15 (0.67) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL29429239 1.00 ALOX15 (0.67) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL30782236 0.88 ALOX15 (0.70) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL19090900 0.87 ECE1 (0.61) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL170878 0.87 KDM4E (0.69) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL2167226 0.87 ALOX15 (0.68) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL170877 0.87 KDM4E (0.69) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL1755294 0.87 ALOX15 (0.68) ALOX15ACESMN1; SMN2KDM4EMAPT
SCHEMBL15226899 0.86 ALOX15 (0.64) ALOX15ACESMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12587105-B2 Power converter MITSUBISHI ELECTRIC CORPORATION (JP) 2026-03-24 US disclosed
US-20250260328-A1 POWER CONVERSION DEVICE MITSUBISHI ELECTRIC CORPORATION (JP) 2025-08-14 US disclosed
US-12319946-B2 Methods for producing modified bacteria for production of nitroaromatics UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2025-06-03 US disclosed
CN-115894574-B Polysubstituted ferrocene-Cu+Chiral material, preparation method and application thereof in electrochemical chiral recognition 常州大学 2025-04-11 CN disclosed
US-20250042961-A1 P53 PEPTIDOMIMETIC MACROCYCLES AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH (SG) 2025-02-06 US disclosed
US-20240417764-A1 METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES MIAMI UNIVERSITY 2024-12-19 US disclosed
US-20240413759-A1 POWER CONVERTER MITSUBISHI ELECTRIC CORPORATION (JP) 2024-12-12 US disclosed
EP-4426676-A2 METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES MIAMI UNIVERSITY (US) 2024-09-11 EP disclosed
US-20240229090-A1 MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-07-11 US disclosed
US-20240159741-A1 NEW TREATMENT AND PREVENTION BASED ON NEW METHOD FOR CONTROLLING CELLULAR IMMUNITY ZERIA PHARMACEUTICAL CO., LTD. (JP) 2024-05-16 US disclosed
WO-2023209821-A1 POWER CONVERSION DEVICE 三菱電機株式会社 2023-11-02 WO disclosed
WO-2023084598-A1 POWER CONVERSION DEVICE 三菱電機株式会社 2023-05-19 WO disclosed
WO-2023081837-A2 METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES MIAMI UNIVERSITY (US) 2023-05-11 WO disclosed
US-20220401545-A1 NOVEL TREATMENT AND PREVENTION OF DISEASE BASED ON IMMUNOLOGICAL MEMORY ZERIA PHARMACEUTICAL CO., LTD. (JP) 2022-12-22 US disclosed
EP-4096786-A1 GENE THERAPY FOR NEURODEGENERATIVE DISORDERS USING POLYNUCLEOTIDE SILENCING AND REPLACEMENT Paros Bio, Inc. (US) 2022-12-07 EP disclosed
WO-2022176920-A1 NEW TREATMENT AND PREVENTION BASED ON NEW METHOD FOR CONTROLLING CELLULAR IMMUNITY ゼリア新薬工業株式会社 2022-08-25 WO disclosed
EP-4014988-A1 NOVEL TREATMENT AND PREVENTION OF DISEASE BASED ON IMMUNOLOGICAL MEMORY National Institutes of Biomedical Innovation, Health and Nutrition (JP) 2022-06-22 EP disclosed
CN-114641309-A Novel immune memory-based disease treatment and prevention 国立研究开发法人医药基盤·健康·荣养研究所 2022-06-17 CN disclosed
WO-2022123653-A1 ELECTRIC POWER CONVERSION UNIT AND ELECTRIC POWER CONVERSION DEVICE 三菱電機株式会社 2022-06-16 WO disclosed
CN-114047238-A L-His-ZIF-8 chiral material, preparation method and application 常州大学 2022-02-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12587105-B2 Power converter PDHB, DUOX2, PDHA1 ALOX15 4307/4885ACE 2330/4885SMN1; SMN2 1314/4885
US-20250042961-A1 P53 PEPTIDOMIMETIC MACROCYCLES TP53, MDM2, MDM4 ALOX15 2855/4885ACE 2541/4885SMN1; SMN2 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.